• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Xspray Pharma

15.50 SEK

+1.57 %

Less than 1K followers

XSPRAY

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.57 %
-36.86 %
-44.64 %
-49.32 %
-49.32 %
-65.58 %
-59.75 %
-83.51 %
-47.22 %

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.

Read more
Market cap
734.96M SEK
Turnover
856.64K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

Press release26.06.2026 klo 09.35

Xspray Pharma provides regulatory update on its US product candidates Nilopki® and Dasynoc® and notes continued progress with its third-party manufacturer NerPharMa

Xspray Pharma
Xspray, Audiocast, Press Release, 2026
Webcast08.06.2026 klo 16.00

Xspray, Audiocast, Press Release, 2026

Xspray Pharma
Press release05.06.2026 klo 17.48

Xspray Pharma to host a conference call regarding Nilopki™

Xspray Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release05.06.2026 klo 01.56

Xspray Pharma Receives CRL from U.S. FDA for Nilopki™

Xspray Pharma
Press release03.06.2026 klo 17.50

Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead

Xspray Pharma
Regulatory press release12.05.2026 klo 12.40

Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026

Xspray Pharma
Regulatory press release30.04.2026 klo 14.00

New number of shares and votes in Xspray Pharma after new share issue April 2026

Xspray Pharma
Regulatory press release28.04.2026 klo 09.00

Interim Report First Quarter 2026

Xspray Pharma
Third party research24.04.2026 klo 09.48

Xspray Pharma: Summer PDUFA dates put launch within reach - Edison

Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer. The oversubscribed rights issue (securing SEK113m in gross proceeds) will remove the principal financing overhang, and any future financing needs are ...

Xspray Pharma
Regulatory press release23.04.2026 klo 09.00

Xspray’s rights issue oversubscribed – over-allotment issue fully utilized

Xspray Pharma
Press release14.04.2026 klo 17.10

FDA accepts trade name Nilopki® for Xspray's drug candidate XS003 (nilotinib)

Xspray Pharma
Regulatory press release09.04.2026 klo 09.00

Notice of annual general meeting of Xspray Pharma AB (publ)

Xspray Pharma
Regulatory press release31.03.2026 klo 09.15

Xspray publishes disclosure document regarding rights issue

Xspray Pharma
Press release26.03.2026 klo 16.55

Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased

Xspray Pharma
Regulatory press release26.03.2026 klo 09.00

Xspray Pharma publishes its Annual Report 2025

Xspray Pharma
Regulatory press release24.03.2026 klo 22.40

Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue

Xspray Pharma
Press release11.03.2026 klo 16.50

Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026

Xspray Pharma
Press release26.02.2026 klo 16.59

Xspray Pharma re-submits its FDA application for Dasynoc

Xspray Pharma
Regulatory press release26.02.2026 klo 08.45

Xspray Pharma appoints Blake Leitch as CEO – Per Andersson continues as Chief Scientific Officer (CSO)

Xspray Pharma
Press release17.02.2026 klo 09.26

Redeye: Xspray Pharma (Q4 Review): A pivotal year ahead

Xspray Pharma